{
    "nct_id": "NCT04179396",
    "official_title": "A Phase 1b, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With Metastatic Castration Resistant Prostate Cancer",
    "inclusion_criteria": "* Have signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form prior to any study-specific evaluation\n* Be ≥18 yrs of age at the time the informed consent form is signed\n* Be either AR-directed therapy-naive or have received 1-2 lines of AR-directed therapy in the castration-resistant setting.\n* Adequate organ function\n* ECOG 0 or 1\n* Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate that is metastatic\n* Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM)\n* Have disease progression after initiation of most recent therapy\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active second malignancy, with the exception of curatively treated non melanoma skin cancer, carcinoma in situ, or superficial bladder cancer\n* Have received greater than 2 previous lines of chemotherapy for mCRPC\n* Prior treatment with any PARP inhibitor\n* Symptomatic and/or untreated central nervous system metastases\n* Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drug\n* Spinal cord compression, symptomatic and/or untreated central nervous system (CNS) metastases or leptomeningeal disease. Patients with asymptomatic previously treated CNS metastases are eligible provided they have been clinically stable for at least 4 weeks\n* Any clinically significant cardiovascular disease\n* Taking any concomitant medications or herbs that could interfere or interact with the study drug",
    "miscellaneous_criteria": ""
}